Auris Medical Holding Ltd. [NASDAQ: EARS] stock went on an upward path that rose over 371.17% on Tuesday, amounting to a one-week price increase of more than 447.07%. The company report on December 1, 2020 that Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection.
Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001). Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection. Over the last 12 months, EARS stock rose by 246.36%. The market cap for the stock reached $36.98 million, with 7.09 million shares outstanding and 6.52 million shares in the current float. Compared to the average trading volume of 2.13M shares, EARS stock reached a trading volume of 303653967 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Auris Medical Holding Ltd. [EARS]:
Euro Pacific Capital have made an estimate for Auris Medical Holding Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 08, 2018. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on April 13, 2017, representing the official price target for Auris Medical Holding Ltd. stock. Previously, the target price had yet another drop from $11 to $5, while Needham kept a Buy rating on EARS stock.
The Average True Range (ATR) for Auris Medical Holding Ltd. is set at 0.47 The Price to Book ratio for the last quarter was 4.84, with the Price to Cash per share for the same quarter was set at 0.00.
EARS Stock Performance Analysis:
Auris Medical Holding Ltd. [EARS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 447.07. With this latest performance, EARS shares gained by 561.94% in over the last four-week period, additionally plugging by 447.76% over the last 6 months – not to mention a rise of 246.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EARS stock in for the last two-week period is set at 97.04, with the RSI for the last a single of trading hit 98.03, and the three-weeks RSI is set at 95.37 for Auris Medical Holding Ltd. [EARS]. The present Moving Average for the last 50 days of trading for this stock 0.96, while it was recorded at 1.94 for the last single week of trading, and 0.96 for the last 200 days.
Insight into Auris Medical Holding Ltd. Fundamentals:
Return on Total Capital for EARS is now -128.24, given the latest momentum, and Return on Invested Capital for the company is -134.33. Return on Equity for this stock declined to -134.33, with Return on Assets sitting at -67.22.
Reflecting on the efficiency of the workforce at the company, Auris Medical Holding Ltd. [EARS] managed to generate an average of -$556,116 per employee.Auris Medical Holding Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.
Auris Medical Holding Ltd. [EARS] Insider Position Details
There are presently around $0 million, or 0.60% of EARS stock, in the hands of institutional investors. The top three institutional holders of EARS stocks are: HRT FINANCIAL LP with ownership of 23,847, which is approximately New of the company’s market cap and around 8.04% of the total institutional ownership; SUSQUEHANNA INTERNATIONAL GROUP, LLP, holding 12,507 shares of the stock with an approximate value of $65000.0 in EARS stocks shares; and ADVISOR GROUP HOLDINGS, INC., currently with $13000.0 in EARS stock with ownership of nearly New of the company’s market capitalization.
Positions in Auris Medical Holding Ltd. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 4 institutional holders increased their position in Auris Medical Holding Ltd. [NASDAQ:EARS] by around 39,330 shares. Additionally, 4 investors decreased positions by around 120,715 shares, while 0 investors held positions by with 120,631 shares. The mentioned changes placed institutional holdings at 39,414 shares, according to the latest SEC report filing. EARS stock had 4 new institutional investments in for a total of 39,330 shares, while 2 institutional investors sold positions of 109,702 shares during the same period.